Inflammatory Bowel Disease (IBD) | Clinical Overview, Causes, Evidence, and Treatment Options (Research Context)

Introduction

Inflammatory bowel disease, usually shortened to IBD, refers mainly to Crohn’s disease and ulcerative colitis. These are chronic inflammatory diseases of the gastrointestinal tract, not the same as irritable bowel syndrome. Crohn’s disease can involve any part of the gastrointestinal tract, while ulcerative colitis affects the colon and rectum (Authority, Authority).

People search for IBD because symptoms can include diarrhea, abdominal pain, blood in stool, urgency, weight loss, fatigue, anemia, flares, and periods of remission. The disease can also involve complications outside the intestine, including joints, skin, eyes, liver, bones, and nutrition status, depending on subtype and disease course (Authority).

Diagnosis is not based on symptoms alone. Clinical evaluation commonly combines history, physical examination, blood tests, stool tests, endoscopy with biopsy, and imaging when needed (Authority).

Treatment categories are chosen by disease subtype, severity, location, complications, prior treatment, and safety context. Guideline-discussed options include anti-inflammatory medicines, corticosteroids, immunomodulators, biologics, targeted oral therapies, nutritional therapy in selected Crohn’s disease settings, and surgery in defined circumstances (Guideline, Guideline).

Informational only; no medical, dosing, or emergency instructions.

Quick Summary

• IBD mainly includes Crohn’s disease and ulcerative colitis, two chronic inflammatory gastrointestinal diseases (Authority, Authority).
• Crohn’s disease can affect any gastrointestinal segment; ulcerative colitis affects the colon and rectum (Authority, Authority).
• Symptoms may include diarrhea, abdominal pain, rectal bleeding, urgency, weight loss, fatigue, and anemia, but symptoms alone do not diagnose IBD (Authority).
• Evaluation usually combines clinical history, laboratory tests, stool tests, endoscopy, biopsy, and imaging when clinically relevant (Authority).
• Guideline-based treatment separates induction of remission from maintenance of remission and varies by disease severity and subtype (Guideline, Guideline).
• Biologics and targeted oral therapies are studied and guideline-discussed for moderate-to-severe IBD, with therapy-specific safety considerations (Guideline, FDA).
• Supplement evidence is strongest for selected agents such as vitamin D, curcumin, and specific probiotic mixtures, but findings remain subtype- and formulation-specific (Review, Review).
• Diet evidence is most developed for selected Crohn’s disease dietary therapies, including exclusive enteral nutrition and Crohn’s disease exclusion diet approaches (Review, Research).
• Low-FODMAP evidence in IBD mainly concerns persistent IBS-like symptoms during quiescent disease, not broad control of active inflammation (Research).
• No topical or cosmetic ingredients met strict direct human-evidence criteria for IBD disease outcomes.

What It Is (Clinical Definition & Classification)

Inflammatory bowel disease is a chronic immune-mediated inflammatory condition of the gastrointestinal tract. The two major clinical entities are Crohn’s disease and ulcerative colitis (Authority, Authority).

Crohn’s disease may involve the small intestine, colon, both, or other gastrointestinal segments. It can be associated with strictures, fistulas, abscesses, perianal disease, malnutrition, and complications outside the gut (Authority).

Ulcerative colitis involves the large intestine and rectum. It is usually described by extent and severity, such as proctitis, left-sided colitis, or more extensive colitis, because extent influences monitoring and treatment decisions (Authority, Guideline).

IBD is not the same as IBS. IBD involves inflammatory tissue injury and objective disease activity markers, while IBS-like symptoms may occur with or without active inflammation and require different clinical interpretation.

Why It Happens (Causes & Risk Factors)

IBD does not have one single cause. It is generally understood as a multifactorial condition involving genetic susceptibility, abnormal immune responses, gut microbiome changes, intestinal barrier dysfunction, and environmental exposures (Authority).

Risk factors and modifiers may include family history, age, smoking patterns, prior infections, antibiotic exposure, geography, diet pattern, stress-related symptom effects, and medication exposures. These factors do not diagnose IBD by themselves.

Crohn’s disease and ulcerative colitis also differ in risk patterns. Smoking has a clearer adverse relationship with Crohn’s disease, while ulcerative colitis has a different epidemiologic pattern. Medication and environmental associations are interpreted at population level, not as individual proof of causation.

Mechanisms / Pathophysiology

In plain language, IBD happens when immune activity in the gut becomes persistent and damaging. The immune system, gut microbes, intestinal lining, and inherited susceptibility interact in a way that causes relapsing inflammation.

Technically, IBD involves dysregulated innate and adaptive immune responses, cytokine signaling, impaired epithelial barrier function, altered microbial ecology, and cycles of mucosal injury and repair. This explains why modern therapies target inflammatory pathways such as TNF, integrins, interleukin pathways, sphingosine-1-phosphate signaling, and JAK signaling (Guideline, Guideline).

Crohn’s disease can produce transmural inflammation, which is one reason strictures, fistulas, and abscesses are important Crohn’s complications. Ulcerative colitis is centered in the colon and rectum mucosa, which is why bleeding, urgency, and colonic extent are central clinical features (Authority, Authority).

Symptoms, Patterns, and Differential Clues

Common IBD symptoms include chronic or recurrent diarrhea, abdominal pain, rectal bleeding, urgency, mucus in stool, weight loss, fatigue, fever during inflammatory activity, anemia, and reduced appetite. Some people also develop inflammation outside the intestine, including joint, skin, eye, liver, and bone-related complications (Authority).

Crohn’s disease patterns can include small-bowel disease, ileocolonic disease, colonic disease, stricturing disease, penetrating disease, and perianal disease. Ulcerative colitis patterns are usually described by colonic extent and severity (Authority).

Conditions that can resemble IBD include gastrointestinal infection, ischemic colitis, medication-related colitis, celiac disease, microscopic colitis, colorectal cancer, and IBS-like symptoms in remission. These are clinical distinctions, not self-diagnosis categories.

Evaluation & Diagnosis (Clinical Context)

IBD evaluation usually begins with symptom history, family history, medication history, physical examination, and assessment of inflammatory and nutritional features. Laboratory and stool tests may evaluate anemia, inflammation, infection, and nutritional status (Authority).

Endoscopy with biopsy is central for evaluating mucosal inflammation and distinguishing ulcerative colitis, Crohn’s disease, infection, and other causes. Imaging may be used to assess small bowel Crohn’s disease, strictures, fistulas, abscesses, and complications (Authority).

Diagnosis also includes classification. Clinicians consider disease subtype, location, extent, severity, inflammatory burden, complications, prior therapies, and safety risks because these factors shape treatment categories and monitoring.

Treatment Options Snapshot (Evidence-Graded, Descriptive Only)

Standard Medical Care (Guidelines)

• Disease classification — IBD care classifies disease by Crohn’s disease versus ulcerative colitis, severity, location, extent, inflammatory burden, complications, and prior treatment history. This classification affects therapy selection and monitoring outcomes. Evidence: Strong. (Guideline, Guideline)
• Induction and maintenance framing — IBD trials and guidelines commonly separate induction of remission from maintenance of remission. A therapy studied for flare control is not automatically a long-term maintenance therapy. Evidence: Strong. (Guideline)
• Objective inflammation assessment — Symptoms are important, but modern IBD care also uses objective markers such as endoscopic findings, histology in selected contexts, imaging, and biomarkers. This reduces overreliance on symptoms alone. Evidence: Moderate. (Authority)
• Complication monitoring — IBD care may include attention to anemia, malnutrition, bone health, strictures, fistulas, abscesses, colorectal cancer risk, and extraintestinal manifestations. The relevant monitoring context differs by disease subtype and duration. Evidence: Strong. (Authority, Authority)
• Safety evaluation for immune therapies — Immune-modifying therapies require safety consideration, including infection risk, malignancy risk, cardiovascular and thrombotic risk for some drug classes, and medication-specific monitoring. JAK inhibitors have FDA safety warnings for serious events in defined contexts. Evidence: Strong. (FDA)

Prescription / Medical Therapies

• Aminosalicylates — Aminosalicylates are guideline-discussed mainly for ulcerative colitis, particularly mild-to-moderate disease contexts. Their role in Crohn’s disease is more limited and should not be generalized across IBD. Evidence: Moderate. (Guideline)
• Corticosteroids — Corticosteroids are used as short-term anti-inflammatory therapies in selected active disease contexts. They are not considered long-term maintenance therapies because safety risks increase with ongoing exposure. Evidence: Strong. (Guideline)
• Immunomodulators — Thiopurines and methotrexate appear in selected maintenance or combination strategies, with differences between ulcerative colitis and Crohn’s disease. These agents require clinical safety monitoring. Evidence: Moderate. (Guideline)
• Biologic therapies — Biologic options target inflammatory pathways such as TNF, integrins, IL-12/23, or IL-23. They are guideline-discussed for moderate-to-severe IBD, but selection depends on disease subtype, severity, prior therapy, complications, and safety profile. Evidence: Strong. (Guideline, Guideline)
• Targeted oral small molecules — JAK inhibitors and sphingosine-1-phosphate receptor modulators are used in defined adult IBD contexts. JAK inhibitor use has specific FDA safety warnings, so class-level risk language should not be omitted. Evidence: Strong. (Guideline, FDA)

Procedures / Devices / Technologies

• Colonoscopy with biopsy — Colonoscopy with biopsy is central for assessing colonic inflammation, histology, extent, and alternative diagnoses. It supports classification but is interpreted with clinical and laboratory context. Evidence: Strong. (Authority)
• Cross-sectional imaging — Imaging is used when small-bowel Crohn’s disease or complications such as strictures, fistulas, or abscesses are being assessed. It provides information that colonoscopy alone may not show. Evidence: Strong. (Authority)
• Endoscopic surveillance — Long-standing colonic IBD can require surveillance for dysplasia and colorectal cancer risk. Surveillance context depends on disease duration, extent, inflammation history, and other risk factors. Evidence: Moderate. (Guideline)
• Surgery for complications or refractory disease — Surgery may be used for strictures, fistulas, abscess complications, dysplasia, cancer, or medically refractory disease. Surgery can remove the diseased colon in ulcerative colitis, while Crohn’s disease can recur in other gastrointestinal sites. Evidence: Strong. (Authority, Authority)
• Nutritional support technologies — Enteral nutrition is studied most clearly in Crohn’s disease, especially pediatric induction contexts. It is a structured nutrition therapy rather than a general supplement category. Evidence: Moderate. (Review)

Supplements / Vitamins (Research Context Only)

Available direct human supplement evidence was more limited than the evidence available for standard medical treatment categories in this condition.

Tier A (Strong / Moderate Evidence)

• Vitamin D — Vitamin D supplementation has been evaluated in IBD trials and meta-analyses, especially in people with low vitamin D status or Crohn’s disease remission contexts. Reported outcomes include relapse risk and disease activity measures, but effects vary by baseline vitamin D status, disease subtype, and trial design. Evidence: Moderate. (Review, Review)
• Curcumin — Oral curcumin has been studied mainly as adjunctive therapy in ulcerative colitis. Trials and meta-analyses reported clinical remission and endoscopic outcomes in some studied populations, but results differ by formulation, dose, background therapy, and trial quality. Evidence: Moderate. (Research, Review)
• Multi-strain probiotics — Specific multi-strain probiotic mixtures have been evaluated in ulcerative colitis and pouchitis-related evidence, not as a universal IBD category. Outcomes include clinical response and remission-related measures, but findings are strain-specific and should not be generalized to all probiotics. Evidence: Moderate. (Review, Research)

Tier B (Limited-Mixed Evidence)

• Omega-3 fatty acids — Omega-3 fatty acids have been studied for Crohn’s disease remission maintenance. Higher-quality evidence reported no reliable improvement in relapse rate, so findings are largely negative for this specific outcome. Evidence: Limited-Mixed. (Review, Research)
• Boswellia serrata extract — Boswellia serrata extract has been evaluated in Crohn’s disease remission maintenance. The studied extract showed tolerability but did not demonstrate superiority over placebo for relapse prevention, limiting disease-specific interpretation. Evidence: Limited-Mixed. (Research)
• Andrographis paniculata extract — A defined Andrographis paniculata extract was tested in adults with mild-to-moderate ulcerative colitis. One studied group showed differences in clinical response, but results are formulation-specific and cannot be applied to all Andrographis products. Evidence: Limited-Mixed. (Research)
• Delayed-release phosphatidylcholine — Modified-release phosphatidylcholine has been studied in ulcerative colitis populations. Outcomes included clinical and endoscopic activity, but the evidence depends on specialized delayed-release formulations rather than ordinary lecithin products. Evidence: Limited-Mixed. (Research)

Tier C (Emerging Evidence)

• Aloe vera gel — Oral aloe vera gel was studied in a small randomized trial in ulcerative colitis. Outcomes included clinical response and histologic activity, but replication is sparse and product composition can vary substantially. Evidence: Emerging. (Research)
• Herbal medicine combinations — Herbal interventions have been evaluated in ulcerative colitis trials and systematic review. Outcomes include clinical remission and response measures, but heterogeneity, product differences, and study quality limit confidence. Evidence: Emerging. (Review)

Dietary Sources (Research Context Only)

• Exclusive enteral nutrition — Exclusive enteral nutrition has been studied mainly in pediatric Crohn’s disease as a complete nutrition-based therapy. Outcomes include clinical remission and nutritional status, but applicability differs by age, adherence, disease phenotype, and clinical setting. Evidence: Moderate. (Review)
• Crohn’s disease exclusion diet plus partial enteral nutrition — This dietary approach has been studied in pediatric and adult Crohn’s disease. Outcomes include clinical remission and sustained remission, but evidence is strongest for Crohn’s disease rather than ulcerative colitis. Evidence: Moderate. (Research, Research)
• Mediterranean-style diet — A randomized trial compared a Mediterranean-style diet with the specific carbohydrate diet in mild-to-moderate Crohn’s disease. Outcomes included symptomatic remission and inflammatory markers, but the trial did not establish broad superiority of one diet for all IBD. Evidence: Moderate. (Research)
• Specific carbohydrate diet — The specific carbohydrate diet has been studied in Crohn’s disease, including randomized comparison with a Mediterranean-style diet. Outcomes included symptom-based remission, but the diet is restrictive and evidence does not support universal IBD benefit. Evidence: Limited-Mixed. (Research)
• Low-FODMAP dietary pattern — Low-FODMAP diets have been tested for persistent IBS-like symptoms in quiescent IBD. Outcomes included symptom score and quality-of-life measures, but this evidence addresses functional symptoms more than active inflammatory control. Evidence: Limited-Mixed. (Research, Research)
• Anti-inflammatory diet pattern — An anti-inflammatory diet was evaluated in ulcerative colitis remission. Outcomes included subclinical colonic inflammation measures, but the evidence is narrow and does not establish a universal flare-treatment diet. Evidence: Emerging. (Research)
• Carrageenan-restricted diet — Carrageenan restriction was studied in a small ulcerative colitis remission trial. The measured outcome was relapse timing, but the evidence is narrow and requires confirmation before broad conclusions. Evidence: Emerging. (Research)

Traditional & Complementary Systems (Research Context)

• Botanical therapies — Botanical therapies have been studied in ulcerative colitis, but findings are product-specific and heterogeneous. The evidence does not support broad claims for all herbal products. Evidence: Limited-Mixed. (Review)
• Mind-body approaches — Stress and coping interventions may be studied around quality of life and symptom perception, but they are not established replacements for inflammation-directed therapy. Outcomes should be framed separately from mucosal healing. Evidence: Emerging. (Authority)
• Acupuncture and related practices — Complementary-practice literature exists, but these approaches are not core guideline therapies for remission induction or mucosal healing. The evidence base is less direct than standard medical therapy. Evidence: Emerging. (Review)
• Dietary therapy traditions — Structured dietary patterns have direct IBD evidence only in specific contexts, especially Crohn’s disease. Results should not be generalized across all IBD subtypes. Evidence: Moderate. (Review)
• Probiotic traditions — Probiotic evidence requires strain-specific and disease-context interpretation. Ulcerative colitis and pouchitis-related findings cannot be generalized to every probiotic or every IBD subtype. Evidence: Moderate. (Review)

What Research Has Studied

• Clinical remission and clinical response in Crohn’s disease and ulcerative colitis (Guideline)
• Endoscopic remission, mucosal healing, and inflammatory burden (Guideline)
• Corticosteroid-free remission and relapse prevention (Guideline)
• Biomarkers such as fecal calprotectin and inflammatory markers in diet and therapy trials (Research)
• Quality-of-life, fatigue, pain, sleep, and social functioning outcomes in dietary trials (Research)
• Pediatric Crohn’s disease growth and nutritional status outcomes in enteral nutrition research (Review)
• Safety outcomes for immune-modifying therapies, including infection and cardiovascular or thrombotic risk for selected classes (FDA)
• Formulation-specific supplement outcomes, especially for curcumin, probiotics, and botanical extracts (Review)

Safety, Interactions & Regulatory Context

IBD treatment safety depends on disease severity, therapy class, immune status, infection risk, pregnancy context, age, comorbidities, prior therapies, and medication-specific risks. Immune-modifying therapies can involve infection screening and monitoring considerations in clinical care (Guideline, Guideline).

JAK inhibitors have specific FDA safety warnings. The FDA communication describes increased risks of serious heart-related events, cancer, blood clots, and death in relevant drug and risk contexts (FDA).

Supplements and botanicals can vary by formulation, contaminants, labeling accuracy, and interaction potential. The IBD supplement literature is uneven, and many commonly marketed products lack direct human IBD outcome evidence (Review).

Dietary restriction can affect nutrient adequacy, growth in children, weight, food anxiety, and adherence. Dietary therapy evidence is strongest in selected Crohn’s disease contexts and narrower for many ulcerative colitis or general IBD claims (Review, Review).

Evidence Overview

The highest-confidence evidence in IBD comes from clinical trials and guideline syntheses of standard medical therapies. Current guidelines discuss biologics, targeted oral small molecules, immunomodulators, corticosteroids, and aminosalicylates according to disease subtype and severity (Guideline, Guideline, Guideline).

Dietary evidence is meaningful but uneven. Exclusive enteral nutrition and Crohn’s disease exclusion diet plus partial enteral nutrition have stronger evidence in Crohn’s disease than most food-source interventions. Mediterranean-style and specific carbohydrate diets have comparative trial data in mild-to-moderate Crohn’s disease, while low-FODMAP evidence mainly concerns IBS-like symptoms in quiescent IBD (Review, Research, Research, Research).

Supplement evidence is narrower than standard therapy evidence. Vitamin D has meta-analytic evidence tied to relapse and disease activity contexts, curcumin has ulcerative-colitis adjunctive trial evidence, and specific probiotic mixtures have subtype- and strain-specific evidence. Omega-3 evidence for Crohn’s remission maintenance is largely negative in higher-quality studies (Review, Research, Review, Review).

Topical and cosmetic ingredient evidence did not meet inclusion criteria for IBD. This does not mean topical prescription rectal therapies are irrelevant to ulcerative colitis care; it means cosmetic-ingredient evidence does not support IBD disease-outcome claims.

Overall, the evidence base is strongest for subtype-specific standard medical care, moderate for selected Crohn’s disease dietary therapies, and limited-mixed to emerging for many supplement and complementary categories.

Evidence Confidence Classification

Overall Rating: Moderate

The overall IBD evidence base is strong for guideline-based diagnosis and standard medical treatment categories, but intervention-layer evidence outside conventional care is uneven. Diet evidence is subtype-specific, supplement evidence is formulation-specific, and no topical/cosmetic ingredient qualified for IBD disease outcomes (Guideline, Guideline, Review, Review).

What Does Not (Evidence Gaps)

• Gluten-free diet without celiac disease — Current dietary evidence does not support a gluten-free diet as a universal IBD inflammation-control therapy. Diet effects are pattern-specific, subtype-specific, and outcome-specific, so broad elimination claims are not supported (Review).
• Fish intake as a substitute for omega-3 capsule trials — Omega-3 supplement evidence in Crohn’s remission maintenance is mostly negative in higher-quality trials, and fish intake evidence cannot be substituted for capsule-trial outcomes. This distinction matters because dietary exposure and supplement trials are not interchangeable (Review, Research).
• General “gut health” supplement blends — Broad blends without direct human IBD outcomes do not meet strict inclusion criteria. Probiotic evidence is strain-specific, formulation-specific, and stronger in some ulcerative colitis or pouchitis-related contexts than broad IBD claims (Review).
• Topical cosmetic ingredients — Cosmetic skin ingredients do not have qualifying direct human evidence for IBD outcomes such as clinical remission, mucosal healing, endoscopic remission, or relapse prevention. IBD is an internal gastrointestinal inflammatory disease, so dermatology outcomes are not disease-outcome evidence (Authority).
• Broad herbal claims — Some herbal therapies have UC trial data, but the evidence is heterogeneous and product-specific. General claims about “herbs for IBD” exceed the evidence base (Review).

FAQ

1. What is IBD? IBD is a chronic inflammatory disease category that mainly includes Crohn’s disease and ulcerative colitis. It involves immune-mediated inflammation in the gastrointestinal tract (Authority, Authority).
2. Is IBD the same as IBS? No. IBD involves inflammatory tissue disease, while IBS is a functional bowel disorder. Some people with IBD in remission can still have IBS-like symptoms, which is a separate clinical issue (Research).
3. What is the difference between Crohn’s disease and ulcerative colitis? Crohn’s disease can affect any part of the gastrointestinal tract. Ulcerative colitis affects the colon and rectum (Authority, Authority).
4. What symptoms are common in IBD? Symptoms can include diarrhea, abdominal pain, rectal bleeding, urgency, weight loss, fatigue, and anemia. Symptoms vary by subtype, severity, and disease location (Authority).
5. How is IBD diagnosed? Diagnosis usually combines medical history, physical examination, blood tests, stool tests, endoscopy with biopsy, and imaging when relevant. Symptoms alone are not enough to classify IBD (Authority).
6. Can IBD go into remission? Yes, many studies and guidelines use remission as a treatment outcome. Remission may refer to symptoms, biomarkers, endoscopic findings, or steroid-free disease control depending on the study or clinical context (Guideline).
7. What medicines are used for IBD? Guideline-discussed categories include aminosalicylates, corticosteroids, immunomodulators, biologics, and targeted oral small molecules. The relevant category depends on subtype and severity (Guideline, Guideline).
8. Are biologics used for both Crohn’s disease and ulcerative colitis? Yes, biologics are used in defined moderate-to-severe Crohn’s disease and ulcerative colitis contexts. Selection depends on disease features and therapy-specific evidence (Guideline, Guideline).
9. Are JAK inhibitors safe for everyone with IBD? No therapy is risk-free. FDA safety communications describe serious risks for JAK inhibitors, including cardiovascular events, cancer, blood clots, and death in relevant contexts (FDA).
10. Can diet cure IBD? Diet has meaningful evidence in selected contexts, especially Crohn’s disease, but it is not established as a universal cure. Dietary evidence is subtype- and outcome-specific (Review).
11. Which diet has the strongest Crohn’s evidence? Exclusive enteral nutrition and Crohn’s disease exclusion diet plus partial enteral nutrition have notable Crohn’s disease evidence, especially in pediatric or selected mild-to-moderate contexts. Applicability differs by age, phenotype, and adherence demands (Review, Research).
12. Is the Mediterranean diet studied in IBD? A Mediterranean-style diet has been compared with the specific carbohydrate diet in mild-to-moderate Crohn’s disease. Outcomes included symptom-based remission and inflammatory markers, but the trial did not prove universal superiority for all IBD (Research).
13. Is a low-FODMAP diet an anti-inflammatory IBD treatment? Low-FODMAP trials in IBD mainly address persistent IBS-like symptoms in quiescent disease. That evidence should not be interpreted as broad treatment of active intestinal inflammation (Research, Research).
14. Do probiotics work for IBD? Some specific probiotic formulations have human evidence in ulcerative colitis and pouchitis-related contexts. The evidence is strain-specific and cannot be generalized to all probiotic products (Review).
15. Does vitamin D treat IBD? Vitamin D has been studied in IBD, with outcomes such as relapse risk and disease activity measures. Evidence is context-dependent and influenced by baseline vitamin D status and disease subtype (Review).
16. Does curcumin have evidence in IBD? Curcumin has human evidence mainly as adjunctive therapy in ulcerative colitis. Findings are not uniform across all formulations or IBD subtypes (Research, Review).
17. Do omega-3 supplements prevent Crohn’s relapse? Higher-quality evidence does not reliably support omega-3 supplements for Crohn’s disease relapse prevention. This is a specific outcome and should not be generalized to all nutrition questions (Review).
18. Are topical skincare ingredients useful for IBD? No topical or cosmetic ingredient met strict direct human evidence criteria for IBD disease outcomes. IBD affects the gastrointestinal tract, and cosmetic skin outcomes do not establish intestinal remission (Authority).
19. Can surgery be part of IBD care? Yes. Surgery may be used for complications, refractory disease, dysplasia, cancer risk, or disease-specific surgical indications. Its role differs between Crohn’s disease and ulcerative colitis (Authority, Authority).
20. Why does evidence differ so much across supplements and diets? IBD includes different diseases, locations, severities, and outcomes. A study in ulcerative colitis remission, pediatric Crohn’s disease, or quiescent IBD symptoms cannot automatically be generalized to all IBD (Review, Review).

Resources

Crohn’s Disease — Authority — https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease
Ulcerative Colitis — Authority — https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
Diagnosis of Crohn’s Disease — Authority — https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease/diagnosis
ACG Clinical Guideline Update: Ulcerative Colitis in Adults — Guideline — https://pubmed.ncbi.nlm.nih.gov/40701556/
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe UC — Guideline — https://pubmed.ncbi.nlm.nih.gov/39572132/
AGA Living Clinical Practice Guideline on Pharmacologic Management of Moderate-to-Severe Crohn’s Disease — Guideline — https://www.gastrojournal.org/article/S0016-5085%2825%2906091-3/fulltext
FDA JAK Inhibitor Safety Communication — FDA — https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk
Vitamin D Supplementation and IBD Disease Activity Meta-analysis — Review — https://pubmed.ncbi.nlm.nih.gov/36579768/
Vitamin D Therapy in Adults With IBD — Review — https://pubmed.ncbi.nlm.nih.gov/32385487/
Curcumin Plus Mesalamine Trial in UC — Research — https://pubmed.ncbi.nlm.nih.gov/25724700/
Curcumin Maintenance Trial in UC — Research — https://pubmed.ncbi.nlm.nih.gov/23076948/
Curcumin Safety and Efficacy in IBD Meta-analysis — Review — https://pubmed.ncbi.nlm.nih.gov/39612780/
Probiotics in IBD Systematic Review — Review — https://pubmed.ncbi.nlm.nih.gov/28653751/
Multi-strain Probiotic Trial in UC — Research — https://pubmed.ncbi.nlm.nih.gov/15984978/
Omega-3 Fatty Acids for Crohn’s Remission Maintenance — Review — https://pubmed.ncbi.nlm.nih.gov/24585498/
Omega-3 Free Fatty Acids Crohn’s Trial — Research — https://pubmed.ncbi.nlm.nih.gov/18398081/
Boswellia Serrata Crohn’s Trial — Research — https://pubmed.ncbi.nlm.nih.gov/20848527/
Andrographis Paniculata Extract UC Trial — Research — https://pubmed.ncbi.nlm.nih.gov/23044768/
Aloe Vera Gel UC Trial — Research — https://pubmed.ncbi.nlm.nih.gov/15043514/
Delayed-Release Phosphatidylcholine UC Trial — Research — https://pubmed.ncbi.nlm.nih.gov/33440385/
Herbal Medicines for Active UC Systematic Review — Review — https://pubmed.ncbi.nlm.nih.gov/38612967/
Exclusive Enteral Nutrition in Crohn’s Disease Review — Review — https://pubmed.ncbi.nlm.nih.gov/29398336/
Crohn’s Disease Exclusion Diet Plus Partial Enteral Nutrition Trial — Research — https://pubmed.ncbi.nlm.nih.gov/31170412/
Crohn’s Disease Exclusion Diet Adult Trial — Research — https://pubmed.ncbi.nlm.nih.gov/34739863/
Specific Carbohydrate Diet vs Mediterranean Diet Trial — Research — https://pubmed.ncbi.nlm.nih.gov/34052278/
Low-FODMAP Diet in Quiescent IBD Trial — Research — https://pubmed.ncbi.nlm.nih.gov/31586453/
Low-FODMAP Diet Six-Week IBD Trial — Research — https://pubmed.ncbi.nlm.nih.gov/31470260/
Anti-inflammatory Diet in UC Remission Trial — Research — https://pubmed.ncbi.nlm.nih.gov/36014800/
Carrageenan-Free Diet UC Trial — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC5389019/
Diet as Treatment for IBD Review — Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC9245150/